Androclus Therapeutics, Inc. Is Granted Patent For Artificial Antigen Presenting Cells.SAN DIEGO & MILAN Milan, prince and king of Serbia Milan (Milan Obrenović) (mĭl`än ōbrĕ`nəvĭch), 1854–1901, prince (1868–82) and king (1882–89) of Serbia; grandnephew of Miloš Obrenović. , ITALY -- Androclus Therapeutics, a biotechnology company developing novel products and technologies for treatment of diseases involving the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. , such as autoimmunity, cancer and infectious diseases, has been granted U.S. Patent No. 6,787,154, entitled, "Artificial Antigen Presenting Cells." This patent is an important addition to the company's revolutionary technology platform known as "T-Cell Capture" (TCC TCC The Car Connection (web site) TCC Tidewater Community College TCC Tallahassee Community College TCC Temporary Continuation of Coverage TCC Tucson Convention Center (Tucson, AZ, USA) ). Artificial antigen presenting cells, the structure of which closely resembles their physiologic equivalents, can induce T-cells to react in a physiologic fashion. This is achieved in an entirely artificial system, in which the composition and relative concentrations of the reagents are fully controllable. The patent claims artificial antigen presenting cell compositions that are broadly applicable to treatment methodologies capable of eliciting up- or down-modulation of an immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. in patients with a need for such modulation. Applications of TCC technology are based on its ability to isolate and manipulate antigen-specific T-cells. Future diagnostic applications of TCC technology include monitoring and evaluation of clinical trials in Inflammation, Autoimmunity and Oncology therapeutic areas, as well as evaluation of vaccine effectiveness. TCC technology has already been applied to monitoring and evaluation of Phase I/IIa clinical trial of Androclus' AT-001 peptide for the treatment of rheumatoid arthritis. Potential therapeutic applications of TCC technology include ex vivo therapy ex vivo therapy Molecular medicine A therapy in which cells or genes are modified out of the body and reintroduced into a person with a genetic disease. See Gene therapy. for otherwise intractable conditions, such as severe infections in immunocompromised immunocompromised /im·mu·no·com·pro·mised/ (-kom´pro-mizd) having the immune response attenuated by administration of immunosuppressive drugs, by irradiation, by malnutrition, or by certain disease processes (e.g., cancer). patients, and therapy of cancer. "Androclus' TCC technology platform enables ex vivo modulation of T-cell responses in an entirely artificial system. The applications are truly far-reaching," said Salvatore Albani, M.D., Ph.D., Androclus scientific founder. "I am pleased that this patent has finally been awarded as it provides a now recognized basis for expanding our patent portfolio with additional patents and significantly strengthens our intellectual property position in the TCC area," said Igor P. Bilinsky, Ph.D., Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . Androclus is looking for strategic partners for further development of TCC technology for both diagnostic and therapeutic applications. About Androclus Therapeutics Androclus Therapeutics is a private biotechnology company with a mission to discover, develop and bring to commercial fruition novel products and technologies for treatment of diseases involving the immune system, such as autoimmunity, cancer and infectious diseases. Androclus' revolutionary technology platform enables up- or down-modulation of patients' immune responses, without the broad immunosuppression immunosuppression Suppression of immunity with drugs, usually to prevent rejection of an organ transplant. Its aim is to allow the recipient to accept the organ permanently with no unpleasant side effects. associated with currently marketed anti-inflammatory drugs. In addition to T Cell Capture technology, Androclus' R&D portfolio includes oral therapeutic peptides for the treatment of rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease inflammatory bowel disease n. Abbr. IBD Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. . For more information, visit Androclus' web site at www.androclus.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion